Table 1.

The association between the co-expression levels of prolactin receptor and transforming growth factor β receptors (PRLR/TGFβRI and PRLR/TGFβRII) in relation to clinicopathological parameters.

PRLR					PRLR
TGFβRII-positive cases	Negative	Positive	% co-expression	p-value	TGFβRI-positive cases	Negative	Positive	% co-expression	p-value
Normal vs. malignant cases
Normal and benign	1	3	75%	0.049		1	4	80%	0.021
Invasive Ca	46	18	28.12%			43	18	29.50%
Histological grade
Grade I	7	3	30%	0.67		8	2	20%	0.72
Grade II	29	10	25.64%			29	10	25.6%
Grade III	11	2	15.38%			11	2	15.38%
LN involvement
LN-negative	23	13	36.11%	0.17		21	13	38.23%	0.38
LN-positive	26	7	21.21%			23	9	28.12%
Tumor size
T1 and T2	22	9	29.03%	0.76		21	9	30%	0.71
T3 and T4	26	9	25.71%			23	8	25.80%
Tumor stage
Stages 1 and 2	26	12	31.57%	0.31		25	13	34.21%	0.38
Stages 3 and 4	23	6	20.68%			19	6	24%
Breast cancer subtype
Luminal	23	10	30.3%	0.29		19	10	34.48%	0.34
HER-2	13	5	27.77%			13	5	27.77%
TNBC	6	0	0%			6	0	0%